Background {#Sec1}
==========

Gastric cancer is the fourth commonest malignancy and the second leading cause of tumor related death all over the world \[[@CR1]\]. Early gastric cancer is a lesion only invading mucosa or submucosa, with or without lymph node metastasis (LNM) \[[@CR2]\]. Early diagnosis of gastric cancer is critical for optimal treatment. The ratio of early gastric cancer at diagnosis is increasing with advanced techniques and screening programs \[[@CR3]\]. As detection of serum tumor markers are more convenient than other approaches, they are widely applied in early diagnosis of gastric cancer \[[@CR4]\]. Unfortunately, the optimal serum biomarker for the detection of early gastric cancer is still under investigation \[[@CR5]\].

The prognosis of early gastric cancer is favorable after radical gastrectomy, with a 5-year overall survival rate exceed 97% \[[@CR6]\]. A variety of factors have been recognized as prognostic factors for early gastric cancer, including tumor size, differentiation status, tumor depth, LNM and vessel involvement \[[@CR7]\]. In addition, tumor markers including CEA \[[@CR8]\], CA19--9 \[[@CR9]\], and AFP \[[@CR10]\] were demonstrated to be prognostic factors for gastric cancer. However, prognostic significance of these markers for early gastric cancer have not been investigated yet.

Given this situation, the present study aims to explore the diagnostic and prognostic significance of CEA, CA19--9, AFP and CA125 for early gastric cancer.

Methods {#Sec2}
=======

This study was carried out in the Xijing Hospital of Digestive Diseases, the Fourth Military Medical University. From September 2008 to March 2015, 587 early gastric cancer patients with radical gastrectomy were enrolled in our present study. This study was approved by the Ethics Committee of Xijing Hospital, and written informed consent was obtained from all patients before surgery.

All patients were treated with proximal, distal or total D2 gastrectomy. The procedure was based on the Japanese Gastric Cancer Treatment Guidelines \[[@CR11]\]. Tumor depth and LNM were defined by pathologists in the department of pathology according to the TNM classification.

Preoperative data including gender, age, tumor location, serum CEA, CA19--9, AFP and CA125 levels were recorded. Tumor size, differentiation status, tumor depth and LNM were collected based on pathology reports. Patients were followed up till November 2016 every 3 months.

The tumor markers were detected within 7 days before surgery. The cut off value of CEA, CA19--9, AFP and CA125 levels were 5 ng/ml, 27 U/ml, 8.1 ng/ml, 35 U/ml. The positive rates of tumor markers were defined as number of cases with elevated markers divided by total number of cases. The positive rates of combined markers were defined as number of cases with elevation in any of the markers divided by total number of cases.

Data were analyzed using SPSS 22.0 for Windows (SPSS Inc., Chicago, IL, USA). Discrete variables were analyzed by Fisher's exact test or Chi-square test. Significant prognostic factors for early gastric cancer patients identified by univariate analysis were further assessed with multivariate analysis using the Cox's proportional hazards regression model. Survival curves for overall survival were obtained using the Kaplan-Meier method**.** The *P* value less than 0.05 was considered to be statistically significant.

Results {#Sec3}
=======

The features of the entire cohort were summarized in Table [1](#Tab1){ref-type="table"}. There were 444 men (75.6%) and 143 women (24.4%). The median age was 57 years (21--85 years). The median follow up time was 39 months (5--75 months). The total number of death during follow up was 25. The 1-, 3- and 5-year overall survival rate was 99.1%, 96.8% and 93.1%, respectively (Fig. [1](#Fig1){ref-type="fig"}).Table 1Clinicopathological characteristics of early gastric cancer patientsCharacteristicsNo. of patientsPercentGender Male44475.6 Female14324.4Age  ≤ 6036862.7  \> 6021937.3Tumor location Upper third10217.4 Middle third10017.0 Lower third38565.6Tumor size (cm)  ≤ 236562.2  \> 222237.8Pathological type Well differentiated18631.7 Moderately differentiated16327.8 Poorly differentiated22037.5 Signet ring cell or Mucinous183.0Tumor depth T1a25543.4 T1b33256.6Lymph node metastasis N049584.3 N1559.4 N2294.9 N381.4 Fig. 1Overall survival of early gastric cancer patients

The positive rates of the four markers were summarized in Table [2](#Tab2){ref-type="table"}. The positive rate of CEA, CA19--9, AFP and CA125 level were 4.3%, 4.8%, 1.5% and 1.9%, respectively. The highest positive rate was 8.2% for combination of two markers (CA19--9 and CEA), 9.4% for combination of three markers (CA19--9, CEA and AFP or CA19--9, CEA and CA125), and 10.4% for combination of all four markers.Table 2Positive rates of single and combined tumor markers in early gastric cancer patientsTumor markerCA19--9AFPCA125CEA25(4.3%)48(8.2%)31(5.3%)35(6.0%)CA19--928(4.8%)37(6.3%)33(5.6%)AFP9(1.5%)20(3.4%)CA12511(1.9%)CEA + CA19--955(9.4%)55(9.4%)CEA + AFP41(7.0%)CA19--9 + AFP44(7.5%)CEA + CA19--9 + AFP61(10.4%)

Considering the extremely low positive rates of AFP and CA125, we only analyzed the correlation between level of CEA and CA19--9 and clinicopathological features. No association was found between CEA level and clinicopathological features (Table [3](#Tab3){ref-type="table"}). However, elevation of CA19--9 level was correlated with female gender and presence of LNM (Table [4](#Tab4){ref-type="table"}).Table 3Comparison of clinicopathological characteristics between two groups stratified by CEA levelCharacteristicsCEA(−)CEA(+)PGender Male422220.161 Female1403Age  ≤ 60351170.675  \> 602118Tumor location Upper third9930.744 Middle third955 Lower third36817Tumor size (cm)  ≤ 2346190.205  \> 22166Pathological type Well differentiated18060.537 Moderately differentiated15310 Poorly differentiated2128 Signet ring cell or Mucinous171Tumor depth T1a24590.539 T1b31716Lymph node metastasis N0474210.698 N1532 N2281 N371 Table 4Comparison of clinicopathological characteristics between two groups stratified by CA 19--9 levelCharacteristicsCA19--9(−)CA19--9(+)PGender Male428160.025 Female13112Age  ≤ 60351170.843  \> 6020811Tumor location Upper third9570.543 Middle third964 Lower third36817Tumor size (cm)  ≤ 2345200.327  \> 22148Pathological type Well differentiated17880.936 Moderately differentiated1567 Poorly differentiated20812 Signet ring cell or Mucinous171Tumor depth T1a243121.000 T1b31616Lymph node metastasis N0475200.020 N1523 N2263 N362

Prognostic factors for early gastric cancer patients were analyzed using univariate analysis (Table [5](#Tab5){ref-type="table"}). The results showed that age, LNM and CEA level were prognostic factors for early gastric cancer. The variables used for adjustment in the multivariate analyses were age, LNM and CEA level. The results showed that age, LNM and CEA level were independent prognostic factors according to multivariate analysis (Table [6](#Tab6){ref-type="table"}). The overall survival of early gastric cancer patients according to the levels of CEA and CA19--9 were shown in Figs. [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"}.Table 5Univariate analysis of prognostic factors for early gastric cancerPrognostic factorsβHazard ratio (95% CI)*P* valueGender0.1051.110(0.443--2.783)0.824Age1.1953.304(1.425--7.661)0.005Tumor location−0.2830.754(0.478--1.189)0.224Tumor size−0.6870.503(0.201--1.260)0.142Pathological type−0.3880.679(0.431--1.067)0.093Tumor depth0.7362.088(0.831--5.241)0.117Lymph node metastasis0.5771.781(1.124--2.821)0.014CEA1.4044.070(1.208--13.713)0.024CA19--90.5761.779(0.419--7.546)0.435AFP−3.0190.049(0.000--590,647.114)0.717CA1250.7402.095(0.283--15.490)0.469 Table 6Multivariate analysis of prognostic factors for early gastric cancerPrognostic factorsβHazard ratio (95% CI)*P* valueAge1.3793.971(1.671--9.435)0.002Lymph node metastasis0.6821.978(1.248--3.136)0.004CEA1.2843.611(1.065--12.245)0.039 Fig. 2Overall survival of early gastric cancer patients stratified by CEA level Fig. 3Overall survival of early gastric cancer patients stratified by CA19--9 level

Discussion {#Sec4}
==========

Serum tumor markers are widely applied in the diagnosis, treatment effect assessment and disease monitoring \[[@CR12]\]. Up to date, a series of studies have explored the diagnostic and prognostic value of various serum tumor markers for gastric cancer \[[@CR5]\]. However, no study has explored the diagnostic and prognostic value of serum tumor markers for early gastric cancer. Our present study found that the positive rates of serum CEA, CA19--9, APF and CA125 were relatively low for early gastric cancer. Elevation of CA19--9 level was correlated with female gender and presence of LNM. Elevation of CEA level was an independent risk factor for the poor prognosis of early gastric cancer.

The positive rates of the four markers for early gastric cancer varied widely. It was reported that the positive rate was 4.4%--15.4% for CEA \[[@CR13]--[@CR15]\], 11.7% for CA19--9 \[[@CR15]\], 2.5%--3.3% for AFP \[[@CR16], [@CR17]\] and 6.7% for CA125 \[[@CR17]\]. In the present study, the positive rates of all four tumor markers were lower than previous reports. Even with the combination of four tumor markers, the positive rate was only 10.4%. This indicated that the diagnostic value of the four tumor markers was extremely low for early gastric cancer.

A strong correlation between elevated tumor markers and clinicopathological features has been reported previously. It was reported that serum CEA level was correlated with tumor depth, LNM \[[@CR13]\] and liver metastasis \[[@CR18]\]. Other studies have reported that CA19--9 level was correlated with tumor depth, LNM and tumor stage \[[@CR19], [@CR20]\]. However, the association between tumor markers and the clinicopathological features of early gastric cancer has not been investigated yet. In our present study, no association was found between CEA level and clinicopathological features. However, elevation of CA19--9 level was correlated with female gender and presence of LNM.

Early gastric cancer has a favorable outcome after radical gastrectomy. The preoperative tumor markers have been reported as valuable predictors for the prognosis of gastric cancer. A meta-analysis containing 14,651 gastric cancer patients demonstrated that serum CEA level was an independent prognostic factor for gastric cancer \[[@CR8]\]. Another meta-analysis revealed that CEA protein and mRNA levels in peritoneal lavage were associated with peritoneal recurrence after radical gastrectomy \[[@CR21]\]. A meta-analysis containing 11,408 gastric cancer patients showed that elevated serum CA19--9 level was correlated with poor prognosis \[[@CR22]\]. Elevated AFP level was reported to be associated with liver metastasis and poor prognosis of gastric cancer \[[@CR10], [@CR23], [@CR24]\]. Elevation of peritoneal lavage CA125 level was correlated with peritoneal dissemination and poor outcomes of gastric cancer \[[@CR25]\]. However, the prognostic value of these tumor markers for early gastric cancer was unclear. In our study, considering the extremely low positive rate of AFP and CA125 level, only the prognostic significance of CEA and CA19--9 level were analyzed. The results showed that serum CEA level was an independent prognostic factor for early gastric cancer. However, serum CA19--9 level had no prognostic significance.

There are some limitations in our study. Firstly, we did not evaluate the predictive value of postoperative levels of serum tumor markers for recurrence patterns and prognosis of early gastric cancer. Secondly, the sample size was not large enough, and the positive rate of tumor markers was relatively low, which may result in bias during analysis. Thirdly, mortality was extremely low in early gastric cancer, which will influence the prognostic significance analysis of tumor markers.

Conclusions {#Sec5}
===========

The positive rates of CEA, CA19--9, APF and CA125 were relatively low for early gastric cancer. Elevation of CA19--9 level was associated with female gender and presence of lymph node metastasis. Elevation of CEA level was an independent risk factor for the poor prognosis of early gastric cancer.
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:   lymph node metastasis
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